CXCL12 and esophageal cancer: Retrospective studies showed that the persistant CXCR4/CXCL12 expression after CRT is associated with tumor aggressiveness and poor prognosis in LARC, esophageal cancer, cervical cancer and glioblastoma 32, 53-55.